Allogeneic mesenchymal stem cells injections for the treatment of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cells transplant

Xing-Wei Liang; Hailong Xia; Yongqing Wang; Robert Chunhua Zhao

doi:10.4172/1948-5956.1000138

Allogeneic mesenchymal stem cells injections for the treatment of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cells transplant

Xing-Wei Liang, Hailong Xia, Yongqing Wang, Robert Chunhua Zhao

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Abstract

Bronchiolitis Obliterans Syndrome (BOS) is a well-recognized complication of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). The management of bronchiolitis obliterans has been frustrating, with patients developing progressive Air Flow Obstruction (AFO). The purpose of this study was to evaluate the efficacy of human Bone Marrow Derived Mesenchymal Stem Cells (BMMSC) as the salvage therapy for BOS after HSCT. One patient with BOS received intravenous infusions of BMMSC at a dose of 1.5×10 ⁶/kg per patients' weight, and rapid recovery from BOS without any side effects was observed. We concluded that BMMSC seems to be a promising therapeutic method in patients with BOS after HSCT.

Original language	English
Pages (from-to)	185-187
Number of pages	3
Journal	Journal of Cancer Science and Therapy
Volume	4
Issue number	7
DOIs	https://doi.org/10.4172/1948-5956.1000138
Publication status	Published - 2012
Externally published	Yes

Keywords

Bronchiolitis obliterans syndrome
Graft-versus-host-disease
Hematopoietic stem cells transplantation
Mesenchymal stem cells

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4172/1948-5956.1000138

Cite this

@article{b5c9bf6d0d81496e824c70ecf4611927,

title = "Allogeneic mesenchymal stem cells injections for the treatment of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cells transplant",

abstract = "Bronchiolitis Obliterans Syndrome (BOS) is a well-recognized complication of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). The management of bronchiolitis obliterans has been frustrating, with patients developing progressive Air Flow Obstruction (AFO). The purpose of this study was to evaluate the efficacy of human Bone Marrow Derived Mesenchymal Stem Cells (BMMSC) as the salvage therapy for BOS after HSCT. One patient with BOS received intravenous infusions of BMMSC at a dose of 1.5×10 6/kg per patients' weight, and rapid recovery from BOS without any side effects was observed. We concluded that BMMSC seems to be a promising therapeutic method in patients with BOS after HSCT.",

keywords = "Bronchiolitis obliterans syndrome, Graft-versus-host-disease, Hematopoietic stem cells transplantation, Mesenchymal stem cells",

author = "Xing-Wei Liang and Hailong Xia and Yongqing Wang and Zhao, {Robert Chunhua}",

year = "2012",

doi = "10.4172/1948-5956.1000138",

language = "English",

volume = "4",

pages = "185--187",

journal = "Journal of Cancer Science and Therapy",

issn = "1948-5956",

publisher = "Hilaris SRL",

number = "7",

}

TY - JOUR

T1 - Allogeneic mesenchymal stem cells injections for the treatment of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cells transplant

AU - Liang, Xing-Wei

AU - Xia, Hailong

AU - Wang, Yongqing

AU - Zhao, Robert Chunhua

PY - 2012

Y1 - 2012

N2 - Bronchiolitis Obliterans Syndrome (BOS) is a well-recognized complication of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). The management of bronchiolitis obliterans has been frustrating, with patients developing progressive Air Flow Obstruction (AFO). The purpose of this study was to evaluate the efficacy of human Bone Marrow Derived Mesenchymal Stem Cells (BMMSC) as the salvage therapy for BOS after HSCT. One patient with BOS received intravenous infusions of BMMSC at a dose of 1.5×10 6/kg per patients' weight, and rapid recovery from BOS without any side effects was observed. We concluded that BMMSC seems to be a promising therapeutic method in patients with BOS after HSCT.

AB - Bronchiolitis Obliterans Syndrome (BOS) is a well-recognized complication of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). The management of bronchiolitis obliterans has been frustrating, with patients developing progressive Air Flow Obstruction (AFO). The purpose of this study was to evaluate the efficacy of human Bone Marrow Derived Mesenchymal Stem Cells (BMMSC) as the salvage therapy for BOS after HSCT. One patient with BOS received intravenous infusions of BMMSC at a dose of 1.5×10 6/kg per patients' weight, and rapid recovery from BOS without any side effects was observed. We concluded that BMMSC seems to be a promising therapeutic method in patients with BOS after HSCT.

KW - Bronchiolitis obliterans syndrome

KW - Graft-versus-host-disease

KW - Hematopoietic stem cells transplantation

KW - Mesenchymal stem cells

UR - http://www.scopus.com/inward/record.url?scp=84866134863&partnerID=8YFLogxK

U2 - 10.4172/1948-5956.1000138

DO - 10.4172/1948-5956.1000138

M3 - Article

AN - SCOPUS:84866134863

SN - 1948-5956

VL - 4

SP - 185

EP - 187

JO - Journal of Cancer Science and Therapy

JF - Journal of Cancer Science and Therapy

IS - 7

ER -

Allogeneic mesenchymal stem cells injections for the treatment of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cells transplant

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this